A recent study indicates that tirzepatide, a widely used diabetes and weight-loss medication, significantly lowers the risk of major cardiovascular events when added to standard care, potentially transforming treatment strategies for high-risk patients.
A commonly used diabetes and weight-loss medicine, tirzepatide, appears to reduce the risk of serious cardiovascular events when added to usual care for people with type 2 diabetes and established heart disease, according to a study published in The BMJ and reported by News Medical. The findings add to a growing body of evidence that GLP-1-based therapies can do more than lower blood sugar and body weight, with prior meta-analyses in PubMed and Nature Medicine also linking the class to fewer major adverse cardiovascular events compared with placebo.
The new analysis drew on US health insurance claims data collected between May 2022 and May 2025 and compared tirzepatide with sitagliptin, a diabetes treatment regarded by the researchers as a neutral comparator because earlier studies have not shown cardiovascular benefit from it. The study included 52,971 adults, with an average age of 70 and just over half women, all of whom had type 2 diabetes, a body mass index of at least 25 and pre-existing cardiovascular disease. Researchers adjusted for factors including age, sex, race, weight, prior heart disease, other illnesses and medication use.
After one year, 2.9% of patients taking tirzepatide had experienced a major cardiovascular event, compared with 4.4% of those taking sitagliptin. That equates to a relative reduction of 32%, and the authors estimate that treating 70 patients with tirzepatide would prevent one such event. The benefit appeared to be driven mainly by fewer heart attacks, with no clear difference in ischaemic stroke. The study also found lower rates of hospital admission for infection, infection-related death and death from any cause.
The results are observational rather than randomised, but the researchers said they had previously tested their design and data systems against a randomised trial framework before drawing causal inferences. They also cautioned that the follow-up period was relatively short, which could mean longer-term benefits or harms were missed, and that the findings may not translate neatly to health systems outside the US or to patients without established cardiovascular disease. A linked editorial said the study offers a useful estimate of what starting tirzepatide might achieve in routine practice, but does not settle questions about mortality indications or the best place for the drug in cardiometabolic treatment pathways.
That caution sits alongside other recent evidence. Cleveland Clinic researchers reported earlier this year that tirzepatide was linked with fewer serious heart and kidney complications than dulaglutide in adults with type 2 diabetes and cardiovascular disease. Separate reviews have also suggested that GLP-1 receptor agonists as a class lower the risk of major cardiovascular events, while a 2022 analysis in Nature Medicine found tirzepatide did not increase cardiovascular risk. Together, the studies point towards a favourable cardiovascular profile, although the practical value of any benefit will depend on access, affordability, supply and whether patients can stay on treatment long enough for that benefit to matter.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
